Zydus receives Phase I clinical trial permission for ZYBKZ from DCGI

ZYBK2 has been specifically designed to inhibit HLA-DRBI Shared Epitope (SE) that determines susceptibility of a person to develop rheumatoid arthritis.

from India Infoline News Service https://ift.tt/2TfemPT